ArticleNature communications2025

CFTR modulator therapy drives microbiome restructuring through improved host physiology in cystic fibrosis: the IMMProveCF phase IV trial.

Rebecca Luise Knoll et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.